Could a Brain-Targeting drug ease Parkinson's dementia symptoms?
NCT ID NCT04470037
First seen Nov 19, 2025 · Last updated Jun 19, 2026 · Updated 25 times
Summary
This completed Phase 2 trial tested a drug called DAAOI-P in 61 people with Parkinson's disease who also have dementia. The goal was to see if the drug could improve walking, reduce falls, and ease neuropsychiatric symptoms. Participants received either DAAOI-P or a placebo pill for a period, and changes were measured using standard rating scales.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DAAOI-P (a drug that modulates NMDA receptors)
What this could lead to
If successful, DAAOI-P could offer a new treatment option to improve movement and behavioral symptoms in people with Parkinson's dementia.
What could go wrong
This is a small Phase 2 trial with only 61 participants, so results may not apply to everyone. The drug may not show clear benefits or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.